Organic Process Research & Development · 2006 · 14 citations · 5 references
PharmacyMedicinal ChemistryDrug DiscoveryPharmaceutical ManufacturingPharmaceutical TechnologyCrystal ChemistryCrystal EngineeringCrystal Habit AnalysisCrystallization ProcessesHigh-throughput SynthesisCrystal Form OptimizationCrystal HabitCrystal Habit ObservationCrystal Habit PolymorphismDrug Crystal FormPharmaceutical Crystals
ABT-492 has been under development at Abbott Laboratories as a quinolone antibiotic. A convergent syntheses was utilized to prepare the compound on a multi-kilogram scale. Difficulties in isolation of intermediates were overcome by developing control of the physical forms. Examples of controlling the agglomeration, crystal habit, and polymorphism of intermediates and the API are described.
5
Stephen M. Berge, Lyle D. Bighley, Donald C. Monkhouse · Journal of Pharmaceutical Sciences · 1977 · 474 citations
R. Docherty, G. Clydesdale, Kevin J. Roberts et al. · Journal of Physics D Applied Physics · 1991 · 415 citations